XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2

Revenues (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:

			Three months ended September 30,												Nine months ended September 30,
			2022						2021						2022						2021
Products:
Kristalose			$	3,903,305					$	4,012,746					$	11,418,673					$	12,286,729
Sancuso			3,960,652						—						10,756,411						—
Vibativ			1,909,750						1,896,584						6,008,005						8,799,891
Caldolor			921,811						1,255,669						3,075,355						3,734,273
Vaprisol			(436)						325,774						(252,059)						1,861,130
Acetadote			99,792						368,733						337,685						638,704
Omeclamox-Pak			35,600						22,689						31,925						(451,683)
RediTrex			85,809						11,459						238,712						(13,291)
Other revenue			496,789						178,886						1,272,562						809,429
Total net revenues			$	11,413,072					$	8,072,540					$	32,887,269					$	27,665,182

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration